APA (7th ed.) Citation

S, P., SA, P., K, S., E, C., B, B., V, G., . . . A, H. (2026). First-in-Human, Phase I Study of Sigvotatug Vedotin, an Integrin Beta-6-Directed Antibody-Drug Conjugate: Results From Dose Expansion in Advanced Non-Small Cell Lung Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 44(17), 1635. https://doi.org/10.1200/JCO-25-02016

Chicago Style (17th ed.) Citation

S, Peters, et al. "First-in-Human, Phase I Study of Sigvotatug Vedotin, an Integrin Beta-6-Directed Antibody-Drug Conjugate: Results From Dose Expansion in Advanced Non-Small Cell Lung Cancer." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 44, no. 17 (2026): 1635. https://doi.org/10.1200/JCO-25-02016.

MLA (9th ed.) Citation

S, Peters, et al. "First-in-Human, Phase I Study of Sigvotatug Vedotin, an Integrin Beta-6-Directed Antibody-Drug Conjugate: Results From Dose Expansion in Advanced Non-Small Cell Lung Cancer." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, vol. 44, no. 17, 2026, p. 1635, https://doi.org/10.1200/JCO-25-02016.